tbuckley/cabot-search huggingface dataset:
Abstract 14482: High-Throughput Drug Screening of iPSC-Derived Vascular Cells to Reverse PAH Phenotype
Authors: Mingxia Gu, Lei Tian, Ning-Yi Shao, Dan Li, Michele Donate, Purvesh Khatri, Joseph Wu, Marlene Rabinovitch
Journal: Circulation (2017)

Pulmonary Arterial Hypertension (PAH) is a progressive disorder characterized by endothelial cell (EC) apoptosis, loss of distal vessels, and occlusive vascular remodeling. Current PAH therapies im...
AB0998 Osteoporosis prevalence in post-menopausal patients treated with aromatase inhibitors using bone mineral density values from a spanish population
Authors: J. Loarce-Martos, W.A. Sifuentes-Giraldo, L.V. Maldonado-Romero, M. Ahijón-Lana, C. Velázquez-Arce, N. Martínez-Jañez, M. Vázquez-Díaz
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Background</h3> The majority of cases of breast cancer (BC) are hormone receptor positive and are sensitive to antiestrogen therapy. For postmenopausal women, adjuvant hormonal therapy with an aromatase inhibitor (AI) is the standard of care, and is associated with greater prevalence of osteoporosis (OP)<sup>1</sup>. Definition of osteoporosis is made depending on the T-Score value, which is calculated according to the bone mass peak obtained from a reference population; in our country, BMD reference values in clinical practice are obtained from the National Health and Nutrition Examination Survey cohort (NHANES III) for femoral neck (FN) and those proportionated by the commercial brand Hologic for lumbar spine (LS), which may not be representative of our population and could be distorting the assessment of OP in our patients. <h3>Objectives</h3> To assess the prevalence of OP in Spanish postmenopausal patients diagnosed with BC and treated with AI using BMD values obtained from a local cohort for T-Score calculation. <h3>Methods</h3> We performed a cross-sectional study with postmenopausal women diagnosed with BC and treated with AI attended in our hospital between <sup>August 2011</sup> and December 2014. We estimated BMD for LS and FN using dual X-Ray absorptiometry. The prevalence of OP in our cohort was assessed using BMD reference values from the Spanish cohort of Diaz-Curiel<sup>2</sup>, which included a group of 2442 healthy patients from both genres stratified by age, and compared it with OP prevalence obtained using clinical practice reference values applied in our country (NHANES III/Hologic). <h3>Results</h3> A total of 54 patients were included. The mean age at diagnosis was 61.50±6.50 years. The AI used in both groups was letrozole. For LS we didn't find statistically significant differences between both groups. For FN we found 13 patients (24%) with OP according to NHANES/Hologic, and 8 patients (14.8%) according to Diaz-Curiel values. These values are summarised in the table. <h3>Conclusions</h3> In our study, we observe statistically significant differences in osteoporosis prevalence for FN, and around 10% of patients could be reclassified using our local BMD values, which highlights the relevance of the use of BMD values obtained from local population for T-score calculation. <h3>References</h3> [1] Becker T, Lipscombe L, Narod S, Simmons C, Anderson GM, Rochon PA. Systematic review of bone health in older women treated with aromatase inhibitors for early-stage breast cancer. J Am Geriatr Soc2012;60:1761–1767. [2] Diaz Curiel M, Garcia JJ, Carrasco JL, Honorato J, Perez Cano R, Rapado A, et al. Prevalence of osteoporosis assessed by densitometry in the Spanish female population. Med Clin (Barc)2001;116:86–88. <h3>Disclosure of Interest</h3> None declared
SAT0539 The frequency of recurrent oral ulcers in famİly members of patİents with behÇet’s disease
Authors: N. Çakir, B. Çelik Yildirim, N. İmeryüz
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Background</h3> It is unknown whether the observed geographic disparities in Behcet's Disease (BD) occurrence reflect primary genetic susceptibility or environmental influences within specific populations. Family aggregation studies may help to discriminate between environmental and genetic components but there are no large family surveys. <h3>Objectives</h3> The aim of this study was to contribute to a better understanding of the genetic aspect of familial aggregation studies in Turkey. <h3>Methods</h3> The study group consisted of siblings and children of 133 unrelated consecutive patients followed up at the BD outpatient clinic in FSM Hospital, İstanbul. Surveyed individuals were interviewed via telephone regarding if they had ever suffered from recurrent oral ulcerations (ROU). Children less than ten years old were surveyed via discussion with their parents. Symptoms and signs of Behçet's disease in family members were also interviewed via telephone. Subjects experience ROU, at least three episodes in one year, were invited to attend further examination, and also were asked whether anyone in their family had BD. <h3>Results</h3> Total 133 patients with BD (86 F, 47 M, respective mean ages: 39.9±11.7, 43.9±10.4 years) had 271 children (137 F, 134 M) and 642 siblings (319 sisters, 323 brothers, respective mean ages: 42.1±13.6, 40.7±14.4 years). All 642 siblings were contacted by telephone; 62 siblings (33 F, 29 M, respective mean ages: 17.9±9.8, 18.2±9.9 years) and 84 children (63 F, 21 M) had positive ROU history. All probands were invited, only 36% family members attended. Apart from patients with BD, 146 family members had ROU (14%). The estimated ROU rate among siblings and children was 9.6%, and 31% respectively. Among members there were 13 patients with BD (2 fathers, 1 mother, 2 children, 3 brothers, 5 sisters). Eleven of these were diagnosed at another centre. We identified 2 additional patients who met ISG criteria during the survey. Only five spouses had ROU (0.5% of members). <h3>Conclusions</h3> In a study from Istanbul, ROU was reported as 9.5% in the general population. In our previous study, that was conducted in an area that was reported as having the lowest prevalence rate of BD, this was estimated as 2.1% in the general population. The ROU rate in the current study for total family members was 16%, and 31% for children, which was higher than in the general population. The rate of patients with BD in the studied cohort, apart from previously diagnosed patients, were 140 per 10, 000 while the reported prevalence rates changed regionally between 20 per 10, 000 and 42 per 10, 000 in Turkey. These findings suggest that BD risk is primarily influenced by genetics rather than environmental conditions. Familial aggregation supports a genetic background for BD <h3>Disclosure of Interest</h3> None declared
A Pilot Study of Brentuximab Vedotin and AVD Chemotherapy Followed By 20 Gy Involved-Site Radiotherapy in Early Stage, Unfavorable Risk Hodgkin Lymphoma
Authors: Anita Kumar, Carla Casulo, Ranjana H. Advani, Lihua Budde, Paul M. Barr, Connie L. Batlevi, Philip Caron, Robert W. Chen, Louis S. Constine, Amanda Courtien, Savita Dandapani, Pamela Drullinsky, Jonathan W. Friedberg, John Gerecitano, Audrey Hamilton, Paul A. Hamlin, Richard T. Hoppe, Steven M. Horwitz, Matthew J. Matasar, Shoshana T. Miller, Alison J. Moskowitz, Ariela Noy, Maria L. Palomba, Carol S. Portlock, Heiko Schoder, David J. Straus, Joanna C. Yang, Anas Younes, Andrew D. Zelenetz, Zhigang Zhang, Joachim Yahalom, Craig H. Moskowitz
Journal: Blood (2017)
Non-canonical cholinergic anti-inflammatory pathway-mediated activation of peritoneal macrophages induces Hes1 and blocks ischemia/reperfusion injury in the kidney
Authors: Tsuyoshi Inoue, Chikara Abe, Takahide Kohro, Shinji Tanaka, Liping Huang, Junlan Yao, Shuqiu Zheng, Hong Ye, Reiko Inagi, Ruth L. Stornetta, Diane L. Rosin, Masaomi Nangaku, Youichiro Wada, Mark D. Okusa
Journal: Kidney International (2019)
Principles and Practice of Endocrinology and Metabolism
Authors: B. Z. Izenstein
Journal: JAMA (2003)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
SAT0074 Identification of a protein panel useful for the prediction of response to methotrexate in rheumatoid arthritis patients
Authors: C. Ruiz-Romero, F. Picchi, L. González-Rodríguez, P. Fernández-Puente, R. Hands, V. Calamia, M. Camacho-Encina, C. Bessant, C. Pitzalis, F.J. Blanco
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Background</h3> The treatment of rheumatoid arthritis (RA) aims to control a patient's signs and symptoms, prevent joint damage, and maintain his/her quality of life. Among the best known disease-modifying antirheumatic drugs, Methotrexate (MTX) is one of the most effective and widely used medications. It is used as a general first-choice drug, although some patients will not respond to this treatment and it is not free from side effects. <h3>Objectives</h3> To identify circulating proteins that could be useful as predictors of the patient's response to MTX. <h3>Methods</h3> Serum samples from patients enrolled in the Pathobiology of Early Arthritis Cohort (PEAC) were collected before treatment with MTX. Response to therapy was determined after 6 months by calculating the initial and final DAS28 of the patients. Their classification was performed following the EULAR response criteria. Sixty samples at baseline from this cohort (30 good responders and 30 non-responders) were depleted from the 14 most abundant proteins by affinity chromatography to remove background. Then, they were analysed by reversed-phase nanoliquid chromatography coupled to mass spectrometry using a SWATH strategy in a tripleTOF MS (Sciex). The quantitative data obtained in this proteomic analysis were processed using the ProteinPilot 5.0.1 and PeakView 2.1 software (Sciex). Machine learning analyses were performed on a train set of 30 samples (15 responders and 15 non-responders) via support vector machine (SVM) using the Classyfire, e1071 and caret R packages. Results were verified in an independent set of 24 samples by a two-stage support vector machine (TSSVM) with RBF kernel and 10 cross-fold validation for each meta-model. <h3>Results</h3> The proteomic analysis led to the identification and quantification of 229 proteins that were common between the screening and validation sets. Independent screening and validation data sets were preprocessed by PCA for dimension reduction and analysed by machine learning tools, leading to the definition of a panel of 8 proteins (one of them involved in MTX metabolism) differentiating the groups of responders and non-responders to MTX with strong agreement (Kappa &gt;0.80), very high accuracy and good relevant metrics (table 1). <h3>Conclusions</h3> We have defined a panel of circulating proteins useful to predict the response to MTX therapy in rheumatoid arthritis patients. <h3>Disclosure of Interest</h3> None declared
Glomerular membrane attack complex is not a reliable marker of ongoing C5 activation in lupus nephritis
Authors: Hannah R. Wilson, Nicholas R. Medjeral-Thomas, Alyssa C. Gilmore, Pritesh Trivedi, Kathleen Seyb, Ramin Farzaneh-Far, Iva Gunnarsson, Agneta Zickert, Thomas D. Cairns, Liz Lightstone, H. Terence Cook, Matthew C. Pickering
Journal: Kidney International (2019)

Complement plays an important role in the pathogenesis of lupus nephritis (LN). With the emergence of therapeutic complement inhibition, there is a need to identify patients in whom complement-driven inflammation is a major cause of kidney injury in LN. Clinical and histopathological data were obtained retrospectively from 57 biopsies with class III, IV, and V LN. Biopsies were stained for complement components C9, C5b-9, C3c, and C3d and for the macrophage marker CD68. C9 and C5b-9 staining were highly correlated (r = 0.92 in the capillary wall). C5b-9 staining was detected in the mesangium and/or capillary wall of both active and chronic proliferative LN in all but one biopsy and in the capillary wall of class V LN in all biopsies. C5b-9 staining intensity in the tubular basement membrane correlated with markers of tubulointerstitial damage, and more intense capillary wall C5b-9 staining was significantly associated with nonresponse to conventional treatment. Glomerular C5b-9 staining intensity did not differ between active and chronic disease; in contrast, C3c and CD68 staining were associated with active disease. Evaluation of serial biopsies and comparison of staining in active and chronic LN demonstrated that C5b-9 staining persisted for months to years. These results suggest that C5b-9 staining is almost always present in LN, resolves slowly, and is not a reliable marker of ongoing glomerular C5 activation. This limits the utility of C5b-9 staining to identify patients who are most likely to benefit from C5 inhibition.Graphical abstract
AB0870 Thirteen-year clinical follow-up of spondyloartrhitis patients: data from the regisponser database
Authors: L. Pérez Sánchez, C. López, P. Font, L. Bautista, M.L. Ladehesa, I. Gómez, A. Escudero, E. Collantes, M.C. Castro
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Objectives</h3> To describe the clinical characteristics of the SpA patients included in the REGISPONSER database during 13 years of follow-up, regarding the evolution of the clinical manifestations and the treatment used. <h3>Methods</h3> An observational and analytical study of a retrospective cohort was carried out, in which 78 patients were analysed at the Reina Sofía University Hospital of Córdoba for the first time in the year 2004/05. The last visit registered was reviewed during the years 2016/17. Data about his clinical condition, including extra-axial manifestations, and treatment was collected. <h3>Results</h3> Seventeen out of 78 SpA patients included in the registry were lost. The characteristics of this cohort are shown in table 1. Recurrence of uveitis was observed in 10 out of 14 (71.4%) patients (p&lt;0.001), with a low recurrence at the end of the follow-up (5%). At the time of inclusion, uveitis was not present in 45 SpA patients, however was present in 8 of them (17.8%) during wollow-up. Three out of the 15 patients who had history of lower limbs peripheral arthritis in the first registry, presented new flares at the end of the study, showing a low level of recurrence (3%). During follow-up, enthesitis was present in 8 out of 45 SpA patients (17.8%) who didn't have a previous history of enthesitis. In adittion, only one episode of dactilitis was detected from the 55 SpA patients who didn't have a previous history of dactilitis. The last CRP value was mean of 5.90 (8.13) mg/dl. Besides, three patients required placement of a hip prosthesis during follow-up. At last visit, we found a response to NSAIDs in 54 patients (88.5%), 33 of them (61.1%) with daily treatment. Biological therapy was present in 25% of the patients,<sup>15</sup> showing a mean time of 18.8 (7.4) years from the appearance of the first symptoms until their indication. A good response was achieved in 50% of patients with the first biologic indicated. Loss of efficacy was the most frecuent cause (62%) of therapy change. Currently golimumab and etanercept are the most commonly used, prescribed in 5 (33%) and 4 (26%) patients respectively. <h3>Conclusions</h3> The results obtained suggest that the follow-up of a cohort of patients with spondyloarthritis in a specialised monographic medical centre allows a control of the symptoms, with a low recurrence of extra-axial manifestations. We can conclude from this study that most patients with spondyloarthritis (75%) could have good control of their disease with NSAIDs in the long term. <h3>Disclosure of Interest</h3> None declared
FRI0134 Is there any difference in ra patients for methotrexate use vs. leflunomide use as a concomitant treatment with biological and targeted synthetic dmards in turkbio registry?
Authors: N. Inanc, G. Ozen, Y. Yalcinkaya, E. Dalkilic, S.S. Koca, G. Can, A. Karataş, Y. Pehlivan, A. Yazıcı, A. Cefle, A. Tufan, S. Akar, S. Senel, B. Oz, N. Akkoc, F. Onen
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Background</h3> TURKBIO registry is the Turkish version of Danish DANBIO rheumatologic database which has been established in 2011. Demographics and previous or current treatment with conventional (csDMARD) and targeted synthetic (tsDMARD), and biological DMARDs (bDMARDs) were collected. <h3>Objectives</h3> We aimed to investigate the efficacy and safety status of methotrexate (MTX) vs. leflunomide (LEF) use as a concomitant treatment with bDMARDs and tsDMARD in this registry. <h3>Methods</h3> Frequencies of achievement of remission or remission +low disease activity (LDA) at the 6th month of bDMARD or tsDMARD treatment were compared between patients who were on these medications with MTX vs. LEF as a concomitant treatment. Drug survival and switch rates of bDMARDs and tsDMARD treatments either with MTX or LEF were compared. The adverse effects with MTX and LEF concomitant use were evaluated as well. <h3>Results</h3> The study included 725 bDMARD or tsDMARD receiving RA patients from 8 participating centres of the TURKBIO registry. Of these patients, 462 (63.7%) were receiving concomitant MTX and 263 (36.3%) LEF. Demographic findings are given in the table 1. Achievement of remission and remission +LDA at the 6th month of bDMARD or tsDMARD initiation was similar in concomitant MTX vs LEF groups (51.4% vs. 53%, p=0.683). When each bDMARD and tsDMARD was evaluated separately, achievement of remission were again similar in MTX and LEF concomitant users (TNFi: 53% vs. 54%; ABA: 50% vs. 59%; RTX: 53% vs. 61%; TCZ: 42% vs. 35%; p&gt;0.05 for all). For TOFA, although remission +LDA rate was numerically higher in MTX concomitant group than LEF group (42% vs. 21%), the difference was not statistically significant due to the smaller sample size of TOFA (n=33). The results were similar for all DMARD groups when remission was evaluated alone. Drug survival (17±12 vs. 16±11 months, p&gt;0.05) and drug discontinuation (42,2 vs 38, p&gt;0.05) rates of bDMARDs or tsDMARD were also not different in MTX vs. LEF concomitant users. Adverse effects rate (19.5% vs 20.5%, p&gt;0.05) were similar between MTX vs. LEF concomitant users as well. <h3>Conclusions</h3> Achievement of remission or remission +LDA was not different with the concomitant use of MTX vs. LEF with any bDMARD or tsDMARD treatment in RA patients with a similar safety profile. LEF might be an alternative as a concomitant DMARD in MTX-intolerant RA patients initiating bDMARDs or tsDMARD. <h3>Disclosure of Interest</h3> None declared
FRI0285 Detection of oligoclonal b-cell populations by spectratyping analysis in the renal tissue of patients with active lupus nephritis
Authors: P. Sfikakis, K. Kolovou, M. Roumelioti, D. Paleologou, M. Tektonidou, C. Kyrtsoni, J. Boletis, P. Panayiotidis, S. Marinaki
Journal: Annals of the Rheumatic Diseases (2018)

Conclusions: This is the first report of increased BBBP in SLE subjects that is specific to the hippocampus; a region that we have previously reported to have abnormal resting metabolism in SLE subjects.These data, including the abnormal NP testing, support the murine model of autoantibody-mediated cognitive impairment following disruption of the BBB.The results also suggest that DCE-MRI may be an effective, non-invasive tool to measure BBBP and its role in neuropsychiatric SLE pending confirmatory studies with increased sample size.
Ivosidenib or Enasidenib Combined with Standard Induction Chemotherapy Is Well Tolerated and Active in Patients with Newly Diagnosed AML with an IDH1 or IDH2 Mutation: Initial Results from a Phase 1 Trial
Authors: Eytan M. Stein, Courtney D. DiNardo, Alice S. Mims, Michael R. Savona, Keith Pratz, Anthony S. Stein, Amir T. Fathi, Richard M. Stone, Daniel A. Pollyea, Olatoyosi Odenike, Bob Lowenberg, Hartmut Döhner, Gary J. Schiller, Ira V. Gupta, Salah Nabhan, Vickie Zhang, Caroline Almon, Michael Cooper, Martin S. Tallman
Journal: Blood (2017)
In Vivo Kinetics of Early, Hypomethylating Agent-Induced Methylome and Transcriptome Changes in Primary AML Blasts: Random or Specific?
Authors: Gabriele Greve, Geoffroy Andrieux, Pascal Schlosser, Nadja Blagitko-Dorfs, Hans-Walter Lindemann, Michael Heuser, Andreas Neubauer, Jürgen Krauter, Helmut R. Salih, Gerhard Heil, Carsten Schwänen, Carsten Müller-Tidow, Arnold Ganser, Hartmut Döhner, Dietmar Pfeifer, Björn Hackanson, Olga Grishina, Melanie Boerries, Michael Lübbert
Journal: Blood (2018)
Spk-8011: Preliminary Results from a Phase 1/2 Dose Escalation Trial of an Investigational AAV-Mediated Gene Therapy for Hemophilia a
Authors: Lindsey A. George, Margaret V. Ragni, Ben J. Samelson-Jones, Adam Cuker, Alexa R. Runoski, Grace Cole, Fraser Wright, Yifeng Chen, Daniel J Hui, Katie Wachtel, Daniel Takefman, Linda B. Couto, Kathleen Z. Reape, Marcus E. Carr, Xavier M. Anguela, Katherine A. High
Journal: Blood (2017)